Intuitive Surgical Falls 5-7% Despite Q3 Beat as $450M Charge and Slowing US Growth Unsettle Investors

Intuitive Surgical reported third-quarter non-GAAP EPS of $3.00, well above the analyst consensus of $2.65, on revenue of $3.05 billion, a 22% jump year over year that also beat expectations. Despite the headline beat, shares fell roughly 5-7% in pre-market trading on October 21 as investors focused on a $450 million litigation settlement charge, narrowed full-year guidance, and US procedure growth of just 10%, which fell short of investor expectations even as global procedure volume rose 15% year over year.

The company placed 315 new da Vinci 5 systems in the quarter, bringing its total installed base to 12,094 systems, a 12% expansion. Gross margin came in above 66%, with full-year gross margin guidance set at approximately 69%, a figure that already reflects a 0.9% headwind from ongoing trade tariffs. The installed base and recurring procedure revenue streams remain a core pillar of the investment case, though the stock's demanding valuation, with a 2027 P/E of roughly 35.5 times and a forward PEG of 2.65, left little room for any growth shortfall.

A notable strategic shift drew analyst attention: Intuitive is pursuing pricing reductions on high-volume benign procedures to broaden its addressable market, prioritizing long-term adoption over near-term revenue per procedure. RBC flagged this approach as a potential risk to 2027 procedure growth momentum. Raymond James lowered its price target on valuation grounds, while Truist reiterated a Buy rating with a $510 target, Stifel reiterated its rating, and Oppenheimer maintained Outperform. Erste Group upgraded ISRG from Hold to Buy, citing the growth outlook. Options volume in ISRG was also flagged as likely to be elevated given the post-earnings volatility.